Precision Medicine

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

A new study confirms AI can detect major heart conditions from one brief ultrasound clip, empowering any clinician to perform life-saving cardiac screening.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

Ossium Health's groundbreaking study using banked bone marrow from deceased donors could solve the critical shortage of transplant matches for patients.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

Canada aims to eliminate cervical cancer by 2040, but rising rates and lagging prevention efforts place the ambitious public health goal at a crossroads.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

The deal merges BlueRidge's broad life sciences support with Design Science's niche expertise in usability, a critical and mandatory field for FDA approval.